Redbiotec, a Swiss developer of a therapeutic vaccine for genital herpes, plans to close CHF 9m Series A round this year
Tags :Vischer
EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, according to Mergermarket
FoRx Therapeutics, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round
VISCHER advised him in this transaction. The team was led by Maxime Chollet (head of Geneva real estate & corporate desks), supported by Nadia Tarolli (tax), Nigar Mustafazade (corporate) and Nina Orth (tax).
From wearables sensors to collect physiological data to DNA’s sequences analysis with AI-based mechanism to online health counseling: numerous digital health solutions are currently being tested, implemented and improved, but Switzerland is still lacking
The Competence Center Banking and Finance at the University of Applied Sciences St.Gallen has started in April 2020 the research project «Independent Evaluation Framework for Security Tokens» co-financed by Innosuisse.
Relief Therapeutics Holding announces the closing of the binding Share Exchange Agreement for the acquisition by Sonnet BioTherapeutics, now a subsidiary of Sonnet BioTherapeutics Holdings
From remote work to brand new services to clients. This is how Law firms in Switzerland are reacting to coronavirus
As for school closing, employees and employers with children will have to find arrangements to deal with this emergency situation
Provinco Italia, subsidiary of Italian Wine Brands (Iwb) has acquired Raphael Dal Bo Ag (Rdb), the Switzerland-based wine maker
